<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00934570</url>
  </required_header>
  <id_info>
    <org_study_id>R-08-259</org_study_id>
    <secondary_id>15590</secondary_id>
    <nct_id>NCT00934570</nct_id>
  </id_info>
  <brief_title>Activity and Metformin Intervention in Obese Adolescents</brief_title>
  <acronym>REACH</acronym>
  <official_title>Reduction of Adolescent Risk Factors for Type 2 Diabetes and Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the sustainability of a two-year intervention aimed at
      improving body mass index (BMI) and metabolic and vascular health in obese youth. The study
      will compare lifestyle changes with diet and exercise alone with changes in lifestyle in
      combination with metformin medication. An initial intensive exercise program will also be
      compared with a standard exercise program.

      Hypothesis: Metformin therapy in combination with intensive lifestyle intervention in obese
      children and adolescents will be associated with reduced rate of weight gain, improved BMI,
      body composition, physical activity, physical fitness, insulin sensitivity, blood lipid
      profiles, adipocytokines and vascular function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the sustainability of a two-year intervention and the degree of
      improvement in body mass index (BMI) and reduction in risk factors for type 2 diabetes and
      diabetes related cardiovascular disease, as well as evaluating the additive effect of
      metformin (as GlumetzaTM 500 mg Extended Release Tablets) and comparing an initial intensive
      exercise program with a standard exercise program. The study will recruit obese youth who are
      at risk for type 2 diabetes and cardiovascular disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in BMI</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in physical activity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin, Standard exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lifestyle intervention with metformin and standard exercise program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Standard exercise</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lifestyle intervention with placebo and standard exercise program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin, Intensive exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lifestyle intervention with metformin and intensive exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Intensive exercise</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lifestyle intervention with placebo and intensive exercise program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and standard exercise</intervention_name>
    <description>Metformin 1500 mg daily for 2 years</description>
    <arm_group_label>Metformin, Standard exercise</arm_group_label>
    <other_name>GlumetzaTM 500 mg Extended Release</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Intensive exercise</intervention_name>
    <description>Metformin 1500 mg daily for 2 years</description>
    <arm_group_label>Metformin, Intensive exercise</arm_group_label>
    <other_name>GlumetzaTM 500 mg Extended Release</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Placebo Standard exercise</intervention_name>
    <description>Standard exercise</description>
    <arm_group_label>Placebo, Standard exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive exercise</intervention_name>
    <description>Placebo Intensive exercise</description>
    <arm_group_label>Placebo, Intensive exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese adolescents defined as BMI greater than the 95th percentile for age and gender

          -  Metformin naive subjects

        Exclusion Criteria:

          -  Elevated fasting plasma glucose ≥ 6.0 mmol/L

          -  2 hour plasma glucose ≥ 11.1 mmol/L after a standard glucose load

          -  A1C &gt; 6.0%

          -  Medication other than &quot;over the counter&quot; drugs, oral contraceptive pill or thyroid
             hormone replacement

          -  Smoking

          -  Pregnancy

          -  Renal insufficiency (serum creatinine &gt; the upper limit of normal)

          -  Hepatic dysfunction (&gt; 1.5 times the upper limit of normal for AST and ALT)

          -  Latex Allergy

          -  Hypersensitivity to metformin or its ingredients

          -  Breast feeding

          -  Subjects with a history of lactic acidosis

          -  Abnormal creatinine clearance

          -  HIV, HBV, and HCV infections

          -  Drug and alcohol abuse

          -  Severe mental disorders

          -  Subjects who are planning radiologic exams involving in i.v. injection of iodinated
             contract materials

          -  Participation in another clinical trial

          -  Significant history or presence of cardiovascular, pulmonary, gastrointestinal,
             immunologic, endocrine, neurologic disorders

          -  Malignant diseases

          -  Previous exposure to any pharmaceutical antidiabetic agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheril Clarson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawson Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital, London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.lhsc.on.ca/About_Us/LHSC/News_Events/Healthy_Eating_and_Activity.htm</url>
    <description>Click here for more information about this study: Metformin and Activity Intervention in Obese Adolescents</description>
  </link>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <last_update_submitted>October 3, 2012</last_update_submitted>
  <last_update_submitted_qc>October 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Cheryl</investigator_full_name>
    <investigator_title>Dr Cheril Clarson</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Metformin</keyword>
  <keyword>Physical activity</keyword>
  <keyword>Cardiovascular health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

